The AMPA receptor positive allosteric modulator, S18986, is neuroprotective against neonatal excitotoxic and inflammatory brain damage through BDNF synthesis

Neuropharmacology

Volumn 57, Issue 3, 2009, Pages 277-286

  Destot Wong, Kim Da ^a,b,c   Liang, Kun ^a,b,c,d   Gupta, Shailesh Kumar ^e   Favrais, Géraldine ^a,b,c   Schwendimann, Leslie ^a,b,c   Pansiot, Julien ^a,b,c   Baud, Olivier ^a,b,c   Spedding, Michael ^f   Lelièvre, Vincent ^a,b,c   Mani, Shyamala ^e   Gressens, Pierre ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PremUP   (France)

^d KUNMING MEDICAL UNIVERSITY   (China)

^e National Brain Research Center   (India)

^f IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Akt; Cell death; ERK; IL 1 ; NMDA

Indexed keywords

2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; IBOTENIC ACID; INTERLEUKIN 1BETA; MESSENGER RNA; WILLARDIINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; EXCITOTOXICITY; FEMALE; GRAY MATTER; MALE; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WHITE MATTER;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BENZOTHIADIAZINES; BRAIN; BRAIN DISEASES; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; MALE; MICE; N-METHYLASPARTATE; NECROSIS; NEUROPROTECTIVE AGENTS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

EID: 67651004686     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.05.010     Document Type: Article

References (63)

1. Arai A., Kessler M., Ambros-Ingerson J., Quan A., Yigiter E., Rogers G., and Lynch G. Effects of a centrally active benzoylpyrrolidine drug on AMPA receptor kinetics. Neuroscience 75 (1996) 573-585
2. Arai A., Kessler M., Xiao P., Ambros-Ingerson J., Rogers G., and Lynch G. A centrally active drug that modulates AMPA receptor gated currents. Brain Res. 638 (1994) 343-346
3. Arai A.C., and Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr. Drug Targets 8 (2007) 583-602
4. Arancio O., and Chao M.V. Neurotrophins, synaptic plasticity and dementia. Curr. Opin. Neurobiol. 17 (2007) 325-330
5. Bemelmans A.P., Horellou P., Pradier L., Brunet I., Colin P., and Mallet J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther. 10 (1999) 2987-2997
6. Bemelmans A.P., Husson I., Jaquet M., Mallet J., Kosofsky B.E., and Gressens P. Lentiviral-mediated gene transfer of brain-derived neurotrophic factor is neuroprotective in a mouse model of neonatal excitotoxic challenge. J. Neurosci. Res. 83 (2006) 50-60
7. Berhow M.T., Hiroi N., and Nestler E.J. Regulation of ERK (extracellular signal regulated kinase), part of the neurotrophin signal transduction cascade, in the rat mesolimbic dopamine system by chronic exposure to morphine or cocaine. J. Neurosci. 16 (1996) 4707-4715
8. Bloss E.B., Hunter R.G., Waters E.M., Munoz C., Bernard K., and McEwen B.S. Behavioral and biological effects of chronic S18986, a positive AMPA receptor modulator, during aging. Exp. Neurol. 210 (2008) 109-117
9. Courtney M.J., Akerman K.E., and Coffey E.T. Neurotrophins protect cultured cerebellar granule neurons against the early phase of cell death by a two-component mechanism. J. Neurosci. 17 (1997) 4201-4211
10. Cramer S.C., and Riley J.D. Neuroplasticity and brain repair after stroke. Curr. Opin. Neurol. 21 (2008) 76-82
11. Dammann O., Kuban K.C., and Leviton A. Perinatal infection, fetal inflammatory response, white matter damage, and cognitive limitations in children born preterm. Ment. Retard. Dev. Disabil. Res. Rev. 8 (2002) 46-50
12. Dicou E., Rangon C.M., Guimiot F., Spedding M., and Gressens P. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain. Brain Res. 970 (2003) 221-225
13. Dolcet X., Egea J., Soler R.M., Martin-Zanca D., and Comella J.X. Activation of phosphatidylinositol 3-kinase, but not extracellular-regulated kinases, is necessary to mediate brain-derived neurotrophic factor-induced motoneuron survival. J. Neurochem. 73 (1999) 521-531
14. Dommergues M.A., Patkai J., Renauld J.C., Evrard P., and Gressens P. Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium. Ann. Neurol. 47 (2000) 54-63
15. Follett P.L., Rosenberg P.A., Volpe J.J., and Jensen F.E. NBQX attenuates excitotoxic injury in developing white matter. J. Neurosci. 20 (2000) 9235-9241
16. Fontaine R.H., Olivier P., Massonneau V., Leroux P., Degos V., Lebon S., El Ghouzzi V., Lelièvre V., Gressens P., and Baud O. Vulnerability of white matter towards antenatal hypoxia is linked to a species-dependent regulation of glutamate receptor subunits. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 16779-16784
17. Gressens P., Marret S., Hill J.M., Brenneman D.E., Gozes I., Fridkin M., and Evrard P. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J. Clin. Invest. 100 (1997) 390-397
18. Gressens P., Spedding M., Gigler G., Kertesz S., Villa P., Medja F., Williamson T., Kapus G., Levay G., Szenasi G., Barkoczy J., and Harsing Jr. L.G. The effects of AMPA receptor antagonists in models of stroke and neurodegeneration. Eur. J. Pharmacol. 519 (2005) 58-67
19. Grether J.K., and Nelson K.B. Maternal infection and cerebral palsy in infants of normal birth weight. JAMA 278 (1997) 207-211
20. Hagberg H., Peebles D., and Mallard C. Models of white matter injury: comparison of infectious, hypoxic-ischemic, and excitotoxic insults. Ment. Retard. Dev. Disabil. Res. Rev. 8 (2002) 30-38
21. Hampson R.E., Rogers G., Lynch G., and Deadwyler S.A. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J. Neurosci. 18 (1998) 2740-2747
22. Hayashi T., Umemori H., Mishina M., and Yamamoto T. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 397 (1999) 72-76
23. Hennigan A., O'Callaghan R.M., and Kelly A.M. Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection. Biochem. Soc. Trans. 35 (2007) 424-427
24. Himmelmann K., Hagberg G., Beckung E., Hagberg B., and Uvebrant P. The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth-year period 1995-1998. Acta Paediatr. 94 (2005) 287-294
25. Husson I., Mesples B., Bac P., Vamecq J., Evrard P., and Gressens P. Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann. Neurol. 51 (2002) 82-92
26. Husson I., Rangon C.M., Lelievre V., Bemelmans A.P., Sachs P., Mallet J., Kosofsky B.E., and Gressens P. BDNF-induced white matter neuroprotection and stage-dependent neuronal survival following a neonatal excitotoxic challenge. Cereb. Cortex 15 (2005) 250-261
27. Ingvar M., Ambros-Ingerson J., Davis M., Granger R., Kessler M., Rogers G.A., Schehr R.S., and Lynch G. Enhancement by an ampakine of memory encoding in humans. Exp. Neurol. 146 (1997) 553-559
28. Johnston M.V., Ferriero D.M., Vannucci S.J., and Hagberg H. Models of cerebral palsy: which ones are best?. J. Child. Neurol. 20 (2005) 984-987
29. Kelly S.J., Bernard K., Muñoz C., Lawrence R.C., Thacker J., Grillo C.A., Piroli G.G., and Reagan L.P. Effects of the AMPA receptor modulator S 18986 on measures of cognition and oxidative stress in aged rats. Psychopharmacology 202 (2009) 225-235
30. Khwaja O., and Volpe J.J. Pathogenesis of cerebral white matter injury of prematurity. Arch. Dis. Child. Fetal Neonatal. Ed. 93 (2008) F153-F161
31. Larroque B., Ancel P.Y., Marret S., Marchand L., Andre M., Arnaud C., Pierrat V., Roze J.C., Messer J., Thiriez G., Burguet A., Picaud J.C., Breart G., and Kaminski M. Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the EPIPAGE study): a longitudinal cohort study. Lancet 371 (2008) 813-820
32. Laudenbach V., Calo G., Guerrini R., Lamboley G., Benoist J.F., Evrard P., and Gressens P. Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain. J. Clin. Invest. 107 (2001) 457-466
33. Lauterborn J.C., Lynch G., Vanderklish P., Arai A., and Gall C.M. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J. Neurosci. 20 (2000) 8-21
34. Lauterborn J.C., Truong G.S., Baudry M., Bi X., Lynch G., and Gall C.M. Chronic elevation of brain-derived neurotrophic factor by ampakines. J. Pharmacol. Exp. Ther. 307 (2003) 297-305
35. Legutko B., Li X., and Skolnick P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 40 (2001) 1019-1027
36. Lelievre V., Hu Z., Byun J.Y., Ioffe Y., and Waschek J.A. Fibroblast growth factor-2 converts PACAP growth action on embryonic hindbrain precursors from stimulation to inhibition. J. Neurosci. Res. 67 (2002) 566-573
37. 3H]noradrenaline release from rat hippocampal and frontal cortex slices. Eur. J. Pharmacol. 401 (2000) 145-153
38. Lockhart B.P., Rodriguez M., Mourlevat S., Peron P., Catesson S., Villain N., Galizzi J.P., Boutin J.A., and Lestage P. S18986: a positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures. Eur. J. Pharmacol. 561 (2007) 23-31
39. Mackowiak M., O'Neill M.J., Hicks C.A., Bleakman D., and Skolnick P. An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology 43 (2002) 1-10
40. Marini A.M., Rabin S.J., Lipsky R.H., and Mocchetti I. Activity-dependent release of brain-derived neurotrophic factor underlies the neuroprotective effect of N-methyl-d-aspartate. J. Biol. Chem. 273 (1998) 29394-29399
41. Mesples B., Plaisant F., Fontaine R.H., and Gressens P. Pathophysiology of neonatal brain lesions: lessons from animal models of excitotoxicity. Acta Paediatr. 94 (2005) 185-190
42. Murray T.K., Whalley K., Robinson C.S., Ward M.A., Hicks C.A., Lodge D., Vandergriff J.L., Baumbarger P., Siuda E., Gates M., Ogden A.M., Skolnick P., Zimmerman D.M., Nisenbaum E.S., Bleakman D., and O'Neill M.J. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2003 (2003) 752-762
43. Nelson K.B., and Chang T. Is cerebral palsy preventable?. Curr. Opin. Neurol. 21 (2008) 129-135
44. Nonomura T., Kubo T., Oka T., Shimoke K., Yamada M., Enokido Y., and Hatanaka H. Signaling pathways and survival effects of BDNF and NT-3 on cultured cerebellar granule cells. Brain Res. Dev. Brain Res. 97 (1996) 42-50
45. O'Neill M.J., Messenger M.J., Lakics V., Murray T.K., Karran E.H., Szekeres P.G., Nisenbaum E.S., and Merchant K.M. Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease. Int. Rev. Neurobiol. 77 (2007) 179-217
46. Plaisant F., Dommergues M.A., Spedding M., Cecchelli R., Brillault J., Kato G., Munoz C., and Gressens P. Neuroprotective properties of tianeptine: interactions with cytokines. Neuropharmacology 44 (2003) 801-809
47. Portera-Cailliau C., Price D.L., and Martin L.J. Excitotoxic neuronal death in the immature brain is an apoptosis-necrosis morphological continuum. J. Comp. Neurol. 378 (1997) 70-87
48. Portera-Cailliau C., Price D.L., and Martin L.J. Non-NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: further evidence for an apoptosis-necrosis continuum. J. Comp. Neurol. 378 (1997) 88-104
49. Rex C.S., Lauterborn J.C., Lin C.Y., Kramar E.A., Rogers G.A., Gall C.M., and Lynch G. Restoration of long-term potentiation in middle-aged hippocampus after induction of brain-derived neurotrophic factor. J. Neurophysiol. 96 (2006) 677-685
50. Russo V.C., Gluckman P.D., Feldman E.L., and Werther G.A. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev. 26 (2005) 916-943
51. Simi A., Tsakiri N., Wang P., and Rothwell N.J. Interleukin-1 and inflammatory neurodegeneration. Biochem. Soc. Trans. 35 (2007) 1122-1126
52. Sizonenko S.V., Bednarek N., and Gressens P. Growth factors and plasticity. Semin. Fetal Neonatal. Med. 12 (2007) 241-249
53. Spedding M., and Gressens P. Neurotrophins and cytokines in neuronal plasticity. In: Chao M. (Ed). Novartis Foundation Symposium (2008), John Wiley & Sons 222-237
54. Staubli U., Perez Y., Xu F.B., Rogers G., Ingvar M., Stone-Elander S., and Lynch G. Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 11158-11162
55. Suppiramaniam V., Bahr B.A., Sinnarajah S., Owens K., Rogers G., Yilma S., and Vodyanoy V. Member of the ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors. Synapse 40 (2001) 154-158
56. Svenningsson P., Bateup H., Qi H., Takamiya K., Huganir R.L., Spedding M., Roth B.L., McEwen B.S., and Greengard P. Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur. J. Neurosci. 26 (2007) 3509-3517
57. Tahraoui S.L., Marret S., Bodenant C., Leroux P., Dommergues M.A., Evrard P., and Gressens P. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter. Brain Pathol. 11 (2001) 56-71
58. Wu D. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx 2 (2005) 120-128
59. Wu X., Zhu D., Jiang X., Okagaki P., Mearow K., Zhu G., McCall S., Banaudha K., Lipsky R.H., and Marini A.M. AMPA protects cultured neurons against glutamate excitotoxicity through a phosphatidylinositol 3-kinase-dependent activation in extracellular signal-regulated kinase to upregulate BDNF gene expression. J. Neurochem. 90 (2004) 807-818
60. Yamamoto N., and Hanamura K. Formation of the thalamocortical projection regulated differentially by BDNF- and NT-3-mediated signaling. Rev. Neurosci. 16 (2005) 223-231
61. Zhu C., Wang X., Huang Z., Qiu L., Xu F., Vahsen N., Nilsson M., Eriksson P.S., Hagberg H., Culmsee C., Plesnila N., Kroemer G., and Blomgren K. Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ. 14 (2007) 775-784
62. Zhu C., Wang X., Xu F., Bahr B.A., Shibata M., Uchiyama Y., Hagberg H., and Blomgren K. The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ. 12 (2005) 162-176
63. Zhu C., Xu F., Wang X., Shibata M., Uchiyama Y., Blomgren K., and Hagberg H. Different apoptotic mechanisms are activated in male and female brains after neonatal hypoxia-ischaemia. J. Neurochem. 96 (2006) 1016-1027